Mf59^®-Adjuvanted Seasonalinfluenza Vaccine

Abstract

Correlated with increasing chronologic age, immunosenescence impairs the response to influenza vaccines. MF59^®-adjuvanted influenza vaccine (Fluad^®, Novartis, Basel, Switzerland) elicits a stronger and broader immune response against well-matched and drifted influenza strains compared with conventional vaccines. MF5-adjuvanted influenza vaccine reduces the rate of hospitalization for pneumonia, cardiovascular disease and cerebrovascular disease, even in seasons with an imperfect match between the vaccine and circulating strains, in vaccinated compared with unvaccinated older adults.

Keywords::

• adjuvant
• antigenic variation
• emulsion
• influenza
• influenza, human
• influenza vaccine
• prevention & control
• squalene
• vaccines, subunit
• vulnerable populations

Financial & competing interests disclosure

Puig-Barberà has received consultancy honoraria from Novartis. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

Puig-Barberà has received consultancy honoraria from Novartis. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.